AuthorisedPhase I and Phase II (Integrated)- OtherInterventional

Research on two creams (Monobenzon / Imiquimod) together with the standard treatment for advanced or metastatic melanoma (ImMI).

This research is investigating new ways to treat advanced melanoma, a type of skin cancer that has spread to other parts of the body. The study is testing two creams, called Monobenzone and Imiquimod, to see how they work when given together with the usual treatments for this condition. It's an early-stage study (Phase I and II), which means researchers are mainly trying to find out if the cream combination is safe for patients and to get an idea of whether it might be effective. Anyone aged 18 or older, regardless of gender, could potentially take part if they meet other specific criteria. This research aims to explore new treatment options for a serious illness.

At a glance

Status

Authorised

Phase

Phase I and Phase II (Integrated)- Other

Sponsor

Amsterdam UMC Stichting

Enrolment target

Start

13 Apr 2026

Malignant Melanoma

What is this study about?

This study is about an important type of skin cancer called melanoma, specifically when it's advanced or has spread to other parts of the body. Doctors call this 'metastatic melanoma'. When melanoma has spread, it can be harder to treat, so researchers are always looking for new and better ways to help patients.

In this particular study, scientists are exploring two different creams: Monobenzone and Imiquimod. They want to see what happens when these creams are used in addition to the standard treatments that patients already receive. The idea is to find out if combining these creams with existing care could offer a new way to fight the cancer.

This is an early-stage research study, known as Phase I and Phase II. This means the main goals are to make sure the creams are safe for people to use together at certain doses and to see if there are any early signs that they could be effective against the cancer. It's not yet about proving a cure, but rather about gathering important information to decide if future, larger studies are worth doing.

Key takeaways

This study is for advanced melanoma, a serious skin cancer.
It tests two creams, Monobenzone and Imiquimod, with standard care.
The main goals are safety and early signs of effectiveness.
It's an early-stage study (Phase I/II), not a guaranteed cure.
Adults aged 18 and over, male or female, can be considered.

Who may be eligible?

To be considered for this study, you would need to be an adult, at least 18 years old. There's no upper age limit mentioned, so older adults could also be considered.

Both men and women are welcome to take part in this research. The study is specifically for people who have advanced melanoma, meaning the skin cancer has spread within the body.

Beyond these general points, there will be other specific health requirements and assessments that a doctor would discuss with you to make sure the study is a good fit and safe for your individual situation.

Quick self-check

I am 18 years old or older.
I have been diagnosed with advanced or metastatic melanoma.
I am willing to attend regular study appointments.
I am interested in exploring new treatment options.
I am comfortable with applying creams as part of my treatment.

This is a guide only — the research team will confirm whether you can take part.

What does participation involve?

If you decide to take part in this study, you would receive the creams being tested (Monobenzone and Imiquimod) alongside your usual standard treatment for advanced melanoma. The study would involve regular appointments at the hospital or clinic. During these visits, the research team would monitor your health carefully, perform examinations, and likely take blood samples to check how you are responding to the treatments and to watch for any side effects. You would also need to record how you are feeling and how your skin reacts to the creams. The total duration of your participation, including how often you apply the creams and how many follow-up visits you would have, would be explained in detail by the study team.

Potential risks and benefits

Taking part in any medical study has potential benefits and risks. A potential benefit of this study is that you would be among the first to try these new creams in combination with standard treatment, which might offer a new option for your advanced melanoma. However, there's no guarantee that the treatment will help everyone or work better than current treatments. Potential risks include side effects from the creams, such as skin irritation, or side effects from the combination of new and standard treatments. It's very important to remember that you have the right to withdraw from the study at any time, for any reason, without it affecting your usual medical care.

Locations (1)

—
Netherlands

Common questions

What type of cancer is this study for?

This study is for advanced or metastatic melanoma, which is a type of skin cancer that has spread to other parts of the body.

What are Monobenzone and Imiquimod?

These are two creams that are being tested in this study alongside standard treatments for advanced melanoma.

Is this a new treatment approach?

Yes, this study is exploring a new approach by combining these two creams with existing standard treatments.

Will I still get my usual cancer treatment?

Yes, the creams are given together with your standard treatment for advanced melanoma.

How old do I need to be to join?

You need to be at least 18 years old to be considered for this study.

How to find out more

Official trial record

Always speak to your GP or specialist before deciding to take part in a study.